ArticleJournal of the American Heart Association2026
Treatment Patterns of Antiseizure Medication for Poststroke Prophylaxis Among Older Adults.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAntiseizure medications are commonly prescribed for poststroke seizures, yet long-term use lacks clear clinical guidance. We examined medication treatment patterns among older adults who initiated levetiracetam, the most frequently prescribed antiseizure medication, within 30 days after an acute ischemic stroke discharge.
methodsWe analyzed a national 20% random sample of US Medicare beneficiaries aged ≥65 years, who were hospitalized for a first acute ischemic stroke between 2009 and 2021 and initiated levetiracetam within 30 days of discharge. To analyze time-varying Levetiracetam treatment patterns over the first year after initiation, we calculated an adjusted proportion of days covered that accounts for prescription overlap, hospitalization, and non-persistence. Adherence to levetiracetam treatment strategy was defined as having a proportion of days covered ≥80%. A latent-class mixed model on proportion of days covered trajectories was applied to identify and characterize different treatment patterns, adjusting for clinical factors.
resultsIn our sample of 1697 levetiracetam initiators, the mean age was 77.5 years, and 58% were women. The latent-class mixed model on proportion of days covered trajectories identified 3 distinct levetiracetam treatment patterns: (1) 907 patients (53%) were nonadherent to treatment after 2 months, (2) 99 patients (6%) were nonadherent to treatment after 10 months, and (3) 691 patients (41%) remained consistently adherent to treatment for at least 1 year. White patients and women were more likely to be adherent to the levetiracetam treatment strategy.
conclusionsApproximately 41% of older adults remained consistently adherent to the levetiracetam treatment strategy within a year after outpatient initiation, with race and sex significantly associated with adherence-to-treatment probabilities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.